- Increased U.S. vaccinations will reduce future demand for COVID-19 testing, severely reducing potential revenue streams.
- Deteriorating fundamentals and low cash-runway will likely result in future share dilution.
- Low institutional ownership coupled with low insider ownership does not instill future confidence in the stock.
- Short interest has increased in the backdrop of the recent price surge.
- Likely that the stock will revert to trading in the $2 range in the next months.
For further details see:
Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke